Optimi Health (OPTH) News
NASDAQ: OPTHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1.51-0.24 (-13.71%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OPTH news summary
We found 4 recent headlines mentioning Optimi Health (OPTH): 2 in the past week and 2 in the past 30 days, most often from Nasdaq, GlobeNewswire. OPTH is making an outsized move today, down 13.71% at $1.51, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Optimi Health Sets 2027 Clinical Agenda; Expects First Ibogaine Capsules Soon", was published by Nasdaq on Nov 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Optimi Health headlines
- Optimi Health Sets 2027 Clinical Agenda; Expects First Ibogaine Capsules Soon(RTTNews) - Optimi Health Corp. (OPTH) on Wednesday outlined its clinical development plans for 2027, including a Phase 2b trial of OPTI-101, a naturally derived psilocybin candidate for major…NasdaqOPTH, BRK.B
- Optimi Health Outlines 2027 Plans for OPTI-101 Phase 2b in Major Depressive Disorder and OPTI-201 Phase 3 in PTSD; Announces Shares-for-Debt SettlementProposed OPTI-101 protocol amendment converts the single-arm, open-label Phase 2 trial into a randomized, double-blind Phase 2b in severe major depressive disorder, enhancing statistical power;…GlobeNewswire
- Optimi Health Completes MDMA Production For Phase 3 PTSD Trial And International Supply(RTTNews) - Optimi Health Corp. (OPTH) announced the completion of a new production batch of its MDMA capsules intended to support a proposed Phase 3 clinical trial for post-traumatic stress disorder…NasdaqOPTH, WSO.B
- Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in AustraliaBatch sufficient to supply the proposed Canadian Phase 3 trial, a clinical trial in Israel in partnership with MAPS and a commercial export to treat PTSD in AustraliaGlobeNewswire